Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLM | Q9NP87 | 2/20 | 0.43 |
| ▸ | POLK | Q9UBT6 | 2/20 | 0.43 |
| ▸ | POLL | Q9UGP5 | 2/20 | 0.43 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | ACR | P10323 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100448 | 0.84 | SLC6A3 (0.59) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL8498857 | 0.84 | SLC6A3 (0.59) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL4182762 | 0.83 | SLC6A3 (0.61) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL12921586 | 0.82 | KDM4E (0.56) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL18803117 | 0.80 | KDM4E (0.57) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL8582948 | 0.80 | SLC6A3 (0.61) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL2525282 | 0.80 | MEN1 (0.65) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL5664646 | 0.80 | MEN1 (0.65) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL7710669 | 0.80 | MEN1 (0.65) | KMT2AKDM4EMEN1RECQLSLC6A3 | |
| SCHEMBL12921590 | 0.80 | PKM (0.56) | KMT2AKDM4EMEN1RECQLSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOCHEMICAL, LLC (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2398761-A2 | CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS | Bezwada Biomedical, LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8062653-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010096320-A2 | CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | KMT2A 4360/4885KDM4E 960/4885MEN1 1770/4885 |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | KMT2A 4360/4885KDM4E 960/4885MEN1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.